Skip to main content
Clinical Trials/IRCT20190707044123N1
IRCT20190707044123N1
Completed
Phase 3

Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patients

Rasht University of Medical Sciences0 sites64 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Rasht University of Medical Sciences
Enrollment
64
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Rasht University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • The diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Psychiatric Disorders (DSM5\)
  • Patients receiving second\-generation drugs
  • A year past diagnosis of schizophrenia
  • Patients have a secondary school education

Exclusion Criteria

  • Sensitivity to famotidine
  • Serious medical illness (Nephrology disease)

Outcomes

Primary Outcomes

Not specified

Similar Trials